Get the Stockscreener App
19.80
3.13%
0.60
After Hours:
20.00
0.20
+1.01%
Dyne Therapeutics Inc stock is traded at $19.80, with a volume of 5.11M.
It is up +3.13% in the last 24 hours and up +19.71% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$19.20
Open:
$20
24h Volume:
5.11M
Relative Volume:
2.85
Market Cap:
$3.27B
Revenue:
-
Net Income/Loss:
$-451.71M
P/E Ratio:
-6.1374
EPS:
-3.2261
Net Cash Flow:
$-462.19M
1W Performance:
+10.31%
1M Performance:
+19.71%
6M Performance:
+6.74%
1Y Performance:
+83.67%
1-Day Range:
$19.14
$20.48
1-Week Range:
$17.64
$20.48
52-Week Range:
$8.06
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
19.80 | 3.17B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dyne awards stock options, RSUs to 6 newly hired employees - Stock Titan
Dyne Therapeutics Inc (DYN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dyne Therapeutics Inc (DYN) Institutional Confidence - TradingKey
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. - Investing News Network
Dyne therapeutics CEO John Cox sells $49,179 in stock - Investing.com UK
Dyne Therapeutics (DYN) CMO auto-sells shares to cover tax withholding - Stock Titan
Dyne Therapeutics (DYN) CCO auto-sells shares to cover RSU tax withholding - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) CEO logs automatic RSU tax sale - Stock Titan
ForDyne B.V. (DYN) reports multiple April 2026 resale lots totaling millions - Stock Titan
Dyne Therapeutics Inc (DYN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dyne Therapeutics Expands Hercules Capital Debt Facility to Up to $400 Million - citybiz
Dyne Therapeutics Shares Rise After Amendment to Debt Facility - marketscreener.com
Dyne Therapeutics, Inc. 8-K SEC Filing: Company Details, Stock Info, and Regulatory Compliance (June 2026) - Minichart
Dyne Therapeutics Expands Loan Facility to $400 Million with Hercules Capital Amendment - marketscreener.com
Dyne Therapeutics amends loan agreement to expand debt facility to $400 million - Investing.com UK
Dyne Therapeutics amends loan facility, secures $50 million - Investing.com
Dyne Therapeutics Expands Hercules Loan Facility to $400 Million, Draws $50 Million Tranche - TradingView
Dyne Therapeutics (NASDAQ: DYN) boosts Hercules loan capacity to $400M - Stock Titan
Dyne Secures $400M War Chest to Push Rare Disease Drugs to Market - BriefGlance
Dyne Therapeutics Secures $125 Million in Additional Financing - Intellectia AI
DYN (Nasdaq: DYN) affiliate sale of 3,311 shares; 9,081 RSUs listed - Stock Titan
DYNE THERAPEUTICS INC (DYN) Stock Chart - ChartMill
Dyne Therapeutics Inc (DYN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Trading Systems Reacting to (DYN) Volatility - Stock Traders Daily
Dyne Therapeutics (DYN) Concludes Phase 1/2 ACHIEVE Trial Enrollment - Insider Monkey
Clearbridge Investments LLC Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Cibc World Market Inc. Takes Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne therapeutics director Brian Posner buys $33,880 in stock By Investing.com - Investing.com Canada
Dyne therapeutics director Brian Posner buys $33,880 in stock - Investing.com
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Director at Dyne Therapeutics (DYN) receives 35,152 stock options - Stock Titan
Director Lubner gets 35,152 Dyne (DYN) options at $17.04 strike - Stock Titan
Dyne Therapeutics director granted 35,152 options | DYN Insider Trading - Stock Titan
Director at Dyne Therapeutics (NASDAQ: DYN) granted 35,152 stock options at $17.04 - Stock Titan
Director at Dyne Therapeutics (DYN) receives grant of 35,152 stock options - Stock Titan
Dyne Therapeutics (DYN) director buys stock and receives 35,152-share option grant - Stock Titan
Dyne Therapeutics (DYN) investors double share authorization and approve all proposals - Stock Titan
Dyne spikes as late-stage trial for Duchenne therapy gets underway - MSN
Dyne Therapeutics (DYN) director Brian Posner buys 2,500 shares in open market - Stock Titan
Dyne Therapeutics (DYN) Reaches Key Regulatory Milestone - Insider Monkey
A Look At Dyne Therapeutics (DYN) Valuation After Key ACHIEVE Trial Enrollment Milestone - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Evercore Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $33 - Moomoo
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $47 - Moomoo
Dyne Therapeutics (DYN) Completes Enrollment in Phase 1/2 ACHIEVE Trial - GuruFocus
How Dyne Therapeutics Inc. (DYN) Affects Rotational Strategy Timing - Stock Traders Daily
Dyne Therapeutics stock hits 52-week low at 17.54 USD By Investing.com - Investing.com Australia
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 - Investing News Network
DYN: BLA filed for DMD, DM1 trial fully enrolled, and robust pipeline advances with strong financials - TradingView
Dyne completes enrollment in DM1 therapy trial expansion cohort By Investing.com - Investing.com Australia
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):